Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
To, B. [1 ]
Farid, S. [1 ]
Zhao, S. [1 ]
Li, M. [1 ]
Amirmokhtari, N. [1 ]
Wei, L. [1 ]
Memmott, R. [1 ]
Alahmadi, A. [1 ]
He, K. [1 ]
Kaufman, J. [1 ]
Roof, L. [1 ]
Shields, P. [1 ]
Carbone, D. [1 ]
Otterson, G. [1 ]
Presley, C. [1 ]
Owen, D. [1 ]
机构：
[1] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
alectinib; dose reduction; CNS disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.10
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [31] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Mu, Lifeng
    Zhou, Benhong
    ADVANCES IN THERAPY, 2020, 37 (02) : 968 - 970
  • [32] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Lifeng Mu
    Benhong Zhou
    Advances in Therapy, 2020, 37 : 968 - 970
  • [33] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
    Lin, Jessica J.
    Zhu, Viola W.
    Schoenfeld, Adam J.
    Yeap, Beow Y.
    Saxena, Ashish
    Ferris, Lorin A.
    Dagogo-Jack, Ibiayi
    Farago, Anna F.
    Taber, Angela
    Traynor, Anne
    Menon, Smitha
    Gainor, Justin F.
    Lennerz, Jochen K.
    Plodkowski, Andrew J.
    Digumarthy, Subba R.
    Ignatius, Sai-Hong
    Shaw, Alice T.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
  • [34] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
    Wang, B.
    Furnback, W.
    Xuan, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [36] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Ahn, M-J
    Crino, L.
    Solomon, Ben
    Zhou, Caicun
    Ou, Sai-hong I.
    Selaru, P.
    Cohen, D. P.
    Bartlett, C. H.
    Kim, Dong-wan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491
  • [37] Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
    Tang, Hao
    Jin, Longyu
    Zhang, Zhang
    Jiang, Zhibin
    Malik, Zeeshan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients.
    Yoshida, Tatsuya
    Oya, Yuko
    Shimizu, Junichi
    Tanaka, Kosuke
    Horio, Yoshitsugu
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Treat, Joseph
    Krzizike, Daniel D.
    Zawislak, Carolyn L.
    Vanderveer, Lisa
    Eidbo, Sarah
    Ross, Eric A.
    Edelman, Martin J.
    Andrews, Andrew J.
    Clapper, Margie L.
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
12345